|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||121.77 - 124.27|
|52 Week Range||92.56 - 141.86|
|Beta (3Y Monthly)||1.79|
|PE Ratio (TTM)||66.20|
|Earnings Date||Jul 24, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||159.12|
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Alexion (ALXN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alexion (ALXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 1 (Strong Buy).
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Alexion Pharmaceuticals today announced that the Company will report its financial results for the second quarter ended June 30, 2019 before the US financial markets open on July 24, 2019.
Alexion Pharmaceuticals Inc NASDAQ/NGS:ALXNView full report here! Summary * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ALXN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ALXN. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $3.99 billion over the last one-month into ETFs that hold ALXN are not among the highest of the last year and have been slowing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Shares of health companies were down Monday, with both the Health Care Select Sector SPDR Fund ETF and the SPDR S&P Pharmaceuticals ETF falling 0.6% in morning intraday trade. Shares of Cardinal Health Inc. led the losers in the S&P 500's health-care ETF, falling 3.1% after the company said CFO Jorge Gomez would leaving the company, followed by declines in shares of Incyte Corp , Alexion Pharmaceuticals Inc. , and Biogen Inc. , Regeneron Pharmaceuticals Inc. and Amgen Inc. . The dip in health-care stocks comes after President Trump's announcement Friday that he was planning to soon issue an executive order allowing the U.S. to buy drugs based on the lowest price paid by other developed countries. "Our guess is drug stocks may be initially pressured this week," Jefferies health-care trading desk strategist Jared Holz wrote in an email to clients on Sunday evening. However, "feedback already suggests investors believe the executive order, if it comes to pass, will only be relevant for a handful of drugs (those that are very significant in revenue and administered in a physician's office)... at least at the onset," he wrote. The drop in health shares comes amid a broader decline in U.S. stocks, as investors grapple with doubts about whether the Federal Reserve will still cut interest rates after a strong U.S. jobs report Friday. The S&P 500 was down 0.4% Monday morning. The index has gained 18.8% in the year to date.
- ULTOMIRIS is the first approved, long-acting complement inhibitor for PNH, administered every other month, reducing the treatment burden for patients -
It can be tough to pick winners in the world of pharmaceutical development, but Alexion, Regeneron, and Ionis offer investors good chances of strong returns.
Alexion Pharmaceuticals, Inc. (ALXN) today announced that the U.S. Food and Drug Administration (FDA) approved SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.1 Approximately three quarters (73%) of all patients with NMOSD test positive for anti-AQP4 auto-antibodies.2 The FDA approved SOLIRIS following an expedited six-month priority review. “Today's approval represents an important milestone for the NMOSD community,” said Victoria Jackson, co-founder of the Guthy-Jackson Charitable Foundation (GJCF), a non-profit organization dedicated to funding research and raising awareness about NMOSD.
Both JPMorgan and Deloitte expect strong merger and acquisition activity ahead, and analysts believe that these stocks are likely targets.
The FDA accepts Alexion's (ALXN) sBLA for Ultomiris under priority review for treating atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy. Shares increase.
We highlight a few leading players from the biotech sector, having surpassed the same so far in 2019 and are likely to put up a good show during the second half of 2019 as well.
Alexion Pharmaceuticals, Inc. (ALXN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the company’s supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, for the treatment of people with atypical hemolytic uremic syndrome (aHUS) in order to inhibit complement-mediated thrombotic microangiopathy (TMA). The FDA has set a target action date of October 19, 2019 under the Prescription Drug User Fee Act (PDUFA). The sBLA is based on previously announced results, which were recently presented at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Congress, from the Phase 3 study of ULTOMIRIS in people with aHUS, which met the primary endpoint of complete TMA response, defined by hematologic normalization and improved kidney function.